The development partners said they will share data with regulators, and AstraZeneca said it will harmonize its share listing across international stock exchanges.

The firms reported promising data from two trials of zipalertinib in patients who have received prior EGFR exon 20-directed therapy and those who haven't.

The funding will support the firm's pipeline of mRNA and gene correction therapies, including an investigational inhaled mRNA therapy under testing for cystic fibrosis.

In an increasingly crowded space, the firm is using streamlined manufacturing and lipid nanoparticle delivery for its in vivo ...

Retrospective research from more than a decade ago demonstrated the potential benefit, but it hadn't been confirmed in a ...

In a new study, Picture Health's QVT score identified responders and non-responders to immunotherapy and chemoimmunotherapy.

The firm commenced a $200 million underwritten public offering, secured $125 million in non-dilutive funding, and refinanced $50 million in debt.

Researchers still see potential for the TIL therapy to benefit patients if combined with other immunotherapies, like checkpoint inhibitors.

The firm said it found its antibody-drug conjugate payload had activity as both a monotherapy and in combination with androgen receptor inhibitors.

The firm has licensed Solid's AAV-SLB101 capsid and plans to fund preclinical development with a potential $1.1 million investment from the Jain Foundation.

The approval follows the CHMP's reversal of a previous decision not to recommend the drug, instead recommending it with certain restrictions.

The company submitted data showing A400's efficacy in patients with advanced RET fusion-positive NSCLC in first- or later-line treatment.